Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). PATIENTS AND METHODS: Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) o...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wick, Wolfgang, Puduvalli, Vinay K., Chamberlain, Marc C., van den Bent, Martin J., Carpentier, Antoine F., Cher, Lawrence M., Mason, Warren, Weller, Michael, Hong, Shengyan, Musib, Luna, Liepa, Astra M., Thornton, Donald E., Fine, Howard A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834468/
https://ncbi.nlm.nih.gov/pubmed/20124186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.2595
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires